Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
4,804 total articles
UiPath is trading like a growth company that lost a step, but the fundamentals and product evolution argue for a tactical long. With ~13% revenue growth, positive free cash flow and a $5.9B market cap, PATH offers exposure to agentic AI orchestration at a modest multiple. This trade plan targets near-term re-rating catalysts while protecting capita…
Netflix is benefiting from price increases, an expanding ad business and fresh live-sports distribution that keep fundamentals healthy. The stock trades near $98.71 with solid technicals and meaningful free cash flow, making a tactical long trade appealing. That said, valuation is rich and consumer-sensitive revenue streams mean you should protect …
Nutrien (NTR) is a top North American fertilizer producer with a $36.3B market cap, trading near $75.48. Recent Middle East disruptions have tightened 30-35% of global fertilizer flows, creating an earnings and pricing tailwind for producers with domestic production and natural gas cost advantages. This trade idea outlines a tactical long into the …
Zoetis (ZTS) sits close to its 52-week low ($113.29) but its valuation remains elevated - P/E ~19.5, P/B ~15, EV ~$56.2B - despite slowing end-market growth and softness across key product segments. I propose a mid-term (45 trading days) short with a clear entry, stop, and target, sized for traders who can tolerate headline risk and wider moves in …
Chevron (CVX) is a conservative way to trade a market elevated oil risk premium from the Iran conflict. The company offers durable cash flow, a 3.5% yield, and a low leverage profile; combine that with oil supply shock dynamics and you get a mid-term trade worth executing around $198.67 with a $230 target and a $185 stop.
Vertex trades off recent weakness after a market pullback. With label expansions boosting chronic revenue streams for ALYFTREK and TRIKAFTA and a cash-generative foundation (free cash flow ~$3.19B, EPS $15.56), the setup favors a long trade sized for a medium-risk profile. Entry, stop and target provided with a clear horizon of 180 trading days.
Broadcom is uniquely positioned across chips, switching, and enterprise software to capture an AI infrastructure and services wave that is still in early innings. This trade idea outlines a long entry with concrete price levels, a multi-month horizon to let product cycles and large enterprise deals materialize, and a clear stop to control downside.
Duolingo is trading at a deeply discounted multiple after a messy pivot away from monetization toward user growth. With $1.04B in revenue, $414M in net income, a healthy free cash flow profile, and a plan to double daily active users to 100M by 2028, the risk/reward favors buyers. This trade idea outlines a disciplined entry at $97.19, a stop at $8…
Cogent (COGT) has clinical momentum: an accepted NDA for bezuclastinib in Non-Advanced Systemic Mastocytosis, robust SUMMIT efficacy signals, Breakthrough Therapy designation in GIST and a multi-NDA path in 2026. The shares trade at a premium - market cap roughly $5.6B - but the risk/reward supports a measured long position into upcoming regulatory…
Adeia has built a deep IP portfolio around hybrid bonding and 3D integration. Recent licensing wins (UMC), strong free cash flow ($156M annual), and accelerating adoption of chiplet architectures create a window for a medium-horizon long trade. Entry $24.87, target $32.00, stop $22.00. Time horizon: mid term (45 trading days).
Ducommun (DCO) is a small-cap aerospace and defense supplier where accelerating missile and defense electronics demand can offset near-term headwinds from Boeing destocking. The balance sheet and EV/sales support a mid-term long trade: entry $126.84, target $140.00, stop $116.00, horizon 45 trading days.
Booz Allen Hamilton plunged after a narrow set of Treasury contract cancellations, but the hit is small relative to the company’s scale. With $933M in free cash flow, a sub-12x P/E, and bullish technicals, this is a tactical long for traders willing to take a mid-term, risk-managed position.
Applied Optoelectronics (AAOI) is riding a wave of AI-driven data center optical demand. Recent multi-hundred-million-dollar orders, stepped-up capacity in Texas and Taiwan, and rapidly improving top-line momentum justify a directional long. Risk is high — valuation and execution matter — but the trade offers a favorable asymmetric payoff if AOI ca…
Ambarella (AMBA) is positioned to benefit from accelerating demand for on-device perception in industrial robotics after recent product launches (CV7) and trade-show exposure. The stock is technically cheap relative to recent momentum, and a mid-term swing trade captures upside from design wins and expanding edge-AI revenue while capping downside w…
Short-term headlines about memory efficiency (TurboQuant) have pressured Micron shares, but the company’s cash flow, tight HBM/SRAM supply for AI accelerators, and a still-reasonable valuation argue for a tactical long. This trade plan targets a move back toward the 52-week highs as markets reprice durable demand, with a clear stop to limit downsid…
Netflix's recent price increases, accelerating ad revenue, and a cleaner balance sheet after walking away from a large M&A bid create a high-probability asymmetric trade into the April 16 earnings report. Valuation is busy but not extreme for a company with $9.46B in free cash flow and an EV/EBITDA of 10.8. Entry at $97.66, stop $85, target $130 ov…
The iShares MSCI South Korea ETF (EWY) is a leveraged way to own Korea's AI-driven memory cycle and corporate reform story. If the Iran war ends and energy-driven risk premia roll off, EWY should re-rate from cyclical discount to growth multiple. We lay out an actionable long trade with entry, stop, targets and a balanced view of catalysts and risk…
UnitedHealth looks like a classic quiet turnaround: core insurance cash flows steady, Optum services margins stabilizing, and tailwinds from Medicare Advantage enrollment and value-based care. This is a tactical long with defined risk management—entry $560.00, stop $520.00, target $640.00—intended for a long-term horizon (180 trading days).
Silgan is a cash-generative packaging platform trading at ~14.6x earnings and EV/EBITDA of 7.7. With roughly $423M of annual free cash flow and current net debt near $3.8B, the company has a clear runway to materially reduce leverage. This trade idea buys the dip and runs the position over the next 180 trading days with a $36.15 stop and $48 target…
Dell combines a durable AI/data-center revenue runway and strong free cash flow with a valuation that still looks reasonable for the current cycle. Buy on a tactical entry near $171 with a $195 target and a $156 stop. Time horizon: long term (180 trading days).
TD SYNNEX looks positioned to reaccelerate revenue quality and margin expansion as Hyve automation deployments move from pilot to scale. I recommend a swing-to-position trade: enter at $120.00, stop at $105.00, target $150.00. Catalyst cadence and improving services mix support upside; execution and macro are the main risks.
Hut 8 reported a headline $248M loss that cleared out expectations, but investors are betting on asset value recovery, operational leverage and potential upside if Bitcoin miners re-rate. This trade idea lays out an actionable long with entry, stop and target, catalysts to watch, and a frank risk framework.
John B. Sanfilippo & Son (JBSS) is a family-run nut processor trading below $1.0 billion market cap, generating solid free cash flow and mid-teens returns on equity. With EPS up sharply in the latest fiscal quarter, conservative balance sheet metrics, and a share base under 12 million, JBSS is a candidate for a measured long trade to capture a mult…
Intel has stopped being the perennial underdog. Recent operational wins - most notably a $14.2B buyback of the minority stake in Ireland's Fab 34 - combined with stronger MLPerf benchmarking activity and improving technicals create a tradeable long. I recommend buying at $48.01, targeting $58.00 over 180 trading days and placing a stop at $43.00. S…
Kura Oncology's approval and NCCN listing for KOMZIFTI (ziftomenib) in relapsed/refractory NPM1-mutant AML shifts the company from pure R&D story to a commercial-stage asset. With a market cap near $735M and enterprise value ~ $597M, early commercial traction, reimbursement wins and label expansion represent asymmetric upside versus a defined downs…
